Pregnancy, breastfeeding, and fertility
Pregnancy
The use of isotretinoin during pregnancy can cause severe congenital malformations in the fetus and may increase the risk of abortion. Pregnancy is an absolute contraindication for treatment with Dercutane 30 mg. Your doctor must ensure that you are not pregnant before starting treatment, and you must avoid pregnancy during the entire treatment and for a month after finishing treatment. If you become pregnant while taking Dercutane 30 mg, stop taking the medication immediately and consult your doctor. |
For more information on pregnancy and contraception, see the “Pregnancy Prevention Plan”, in the “Warnings and Precautions” section.
Breastfeeding
You should not take Dercutane 30 mg during breastfeeding because isotretinoin may pass into breast milk and harm the baby. |
Fertility
There is no evidence to suggest that fertility or offspring of men are affected by taking isotretinoin.
Driving and using machines
Dercutane 30 mg may cause a decrease in night vision that may appear suddenly during treatment. Rarely, these disturbances persist after stopping medication. If you notice these or other visual effects, or if you feel drowsy or dizzy, you should not drive, use machines, or engage in any activity that may put you or others at risk.
Dercutane 30 mg contains soy oil, sodium, and sorbitol
Thismedicationcontains 15.05mg of sorbitol (E420) in each capsule.
This medication contains less than 23 mg of sodium (1 mmol) per capsule; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication. Your doctor will indicate the duration of your treatment with Dercutane 30 mg. Do not discontinue treatment before.
Other presentations are available based on the recommended dosage by your doctor.
The capsules are taken with food, once or twice a day. You must swallow the capsules whole without crushing or sucking them.
Use in adults, including adolescents and elderly people
Usually, treatment starts with a dose of 0.5 mg per kilogram of body weight and day (0.5 mg/kg/day). Your doctor may adjust this dose after a few weeks based on your response to treatment. The dose varies between 0.5 and 1.0 mg/kg/day in most cases.
Before starting treatment with Dercutane 30 mg, consult the “Pregnancy Prevention Plan”, in the “Warnings and Precautions” section.
Use in patients withsevererenalfunction impairment
Treatment should start with the lowest dose and increase it later.
Use in children
Dercutane 30 mg is not indicated for treating acne that appears before puberty or in children under 12 years old.
The usual treatment cycle lasts 16 to 24 weeks. Acne may continue to improve up to 8 weeks after treatment is completed. Most patients only need one treatment cycle.
If you estimate that the effect of Dercutane 30 mg is too strong or too weak, inform your doctor or pharmacist.
If you take more Dercutane 30 mg than you should
If you have taken more Dercutane 30 mg than you should, consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or the nearest hospital or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Dercutane 30 mg
Do not take a double dose to compensate for the missed dose.
In case of a missed dose, take the medication as soon as possible and continue treatment as prescribed. However, when the next administration is near, do not take the missed dose and wait for the next administration.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Generally, such side effects resolve as treatment continues. Your doctor will help you manage them if they occur.
Severe side effects
Mental problems
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Immediately contact your doctor if you experience any of these mental problems.Your doctor may prescribe you to stop taking Dercutane 30 mg. This may not be enough to stop the effects: you may need more help, and your doctor can manage it.
It is very important that you inform your doctor if you have suffered from any disease such as depression, suicidal behavior, or psychosis and if you are receiving any medication for the treatment of these diseases.
Other severe side effects
Rare(may affect up to 1 in 1,000 people):
Allergic reactions:allergic reaction with chest tightness or difficulty breathing (especially if you are asthmatic) with skin rashes and itching. If you experience an allergic reaction, treatment must be interrupted immediately and you must consult with your doctor.
Very rare (may affect up to 1 in 10,000 people):
Increased intracranial pressure (of the brain):in very rare cases, when isotretinoin is administered with some antibiotics (tetracyclines), increased intracranial pressure, seizures, and drowsiness have been observed. If you are affected by persistent headache with nausea, vomiting, and blurred vision, this may mean that you are suffering from benign intracranial hypertension. Stop taking isotretinoin as soon as possible and consult your doctor.
Gastrointestinal alterations: pancreatitis (pancreas inflammation), gastrointestinal hemorrhage (blood in the stool), colitis, ileitis (intestinal inflammation), and inflammatory bowel disease. If you experience severe abdominal painwith or without severe diarrhea with blood, and vomiting, stop taking isotretinoin as soon as possible and consult your doctor.
Liver alterations: hepatitis. If your skin or eyes turn yellow and you feel tired, stop taking your medication as soon as possible and consult your doctor.
Kidney alterations: glomerulonephritis (kidney inflammation). You may feel excessively tired, stop urinating, and have inflamed and swollen eyelids. If this happens while you are taking your medication, suspend the treatment with this medication and consult your doctor.
Unknown frequency (cannot be estimated from available data):
Skin alterations: severe skin rash (erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis) that may be life-threatening and require immediate medical attention. They initially appear as circular patches, often with a central blister, usually on arms and hands or legs and feet; more severe rashes may also include blisters on chest and back. Additionally, they may present symptoms such as eye infection (conjunctivitis) or ulcers in the mouth, throat, or nose. More severe forms of skin rash may lead to generalized skin peeling that may be life-threatening. These types of skin rash may often be preceded by headache, fever, body aches (symptoms similar to the flu).
Immediately stop taking this medication and contact your doctor if you present this type of skin symptoms.
Mild side effects
Very common(may affect more than 1 in 10 people):
Skin and eye alterations:dry skin, lips, and face. You may have throat or skin inflammation, skin or lip dryness, itching, or mild peeling. This dryness can be reduced with regular use of a good moisturizing cream from the beginning of treatment.
You may feel your eyes irritated or with conjunctivitis, itching, and redness. You may also notice swollen eyelids. Normally, these side effects are reversible once treatment is stopped.
Musculoskeletal and bone alterations: back pain, muscle pain, and joint pain. These side effects are reversible once you stop treatment. You should try to reduce intense physical activity during isotretinoin treatment.
Blood and urine analytical alterations: decreased hemoglobin in blood (anemia), decreased or increased platelets, increased liver enzymes (transaminases), increased triglycerides in blood, and decreased certain fats (high-density lipoproteins).
Common(may affect up to 1 in 10 people):
Blood and urine analytical alterations: decreased white blood cells that may make you more susceptible to infections, increased cholesterol in blood, increased blood sugar, detection of proteins or blood in urine.
Nervous system disorders: headache.
Respiratory disorders: nasal bleeding, dry nose, or throat and nasal inflammation.
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Other side effects that may occur are the following:
Unknown frequency(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store theblisterin theouter packagingto protect them from light and moisture.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the box after CAD.:. The expiration date is the last day of the month indicated.
Do not use this medication if you observe visible signs of deterioration.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medicines at the SIGRE point of the pharmacy. Ask your pharmacist how to dispose of packaging and unused medicines. This will help protect the environment.
Return unused capsules to your pharmacist. Store them only if your doctor instructs you to..
Composition of Dercutane 30 mg:
Appearance of the product and contents of the package
Dercutane 30 mg is presented in the form of soft capsules, each capsule has a pink-colored coating containing a viscous, opaque yellow/orange liquid. Each package contains 30 or 50 soft capsules. Some package sizes may only be marketed.
Marketing authorization holderandresponsibleformanufacturing
Marketing authorization holder:
INDUSTRIAL FARMACEUTICA CANTABRIA, S.A.
Barrio Solía 30,
La Concha de Villaescusa
39690 Cantabria (Spain)
Responsible for Manufacturing:
TOLL MANUFACTURING SERVICES, S.L.
C/ Aragoneses 2,
28108 Alcobendas (Madrid)
Spain
or
INDUSTRIAL FARMACEUTICA CANTABRIA, S.A.
C/ Pirita, 9
28850 Torrejón de Ardoz (Madrid)
Spain
or
EDEFARM, S.L.
Polígono Industrial Enchilagar del Rullo, 117
46191 Villamarchante (Valencia)
Spain
Last review date of thisprospecto:February 2024
Detailed andupdatedinformation about this product is available by scanning the QR code included in the prospecto through a smartphone. The same information is also available at the following link:http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.